RxDoctor Payments Data

Michael Domalakes, MD

Internal Medicine · Omaha, NENPI 1740395946

Payments from drug & device makers

$441in general payments, 2019–2025

Across 25 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$167
  • Novo Nordisk$69
  • Boston Scientific$44
  • Pfizer$42
  • GSK$33
  • Amgen$27
  • plus $59 from 4 others

What the payments were for

  • Food & beverage$441100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$441 in reported general payments places this provider in the 70th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$202,214
Medicare patients
651
Services billed
12,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban175$183,336
TrulicityDulaglutide58$75,878
OzempicSemaglutide63$66,313
MounjaroTirzepatide52$59,530
JardianceEmpagliflozin44$58,346
XareltoRivaroxaban53$46,531
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$33,897
JanuviaSitagliptin Phosphate46$30,359
Bydureon BciseExenatide Microspheres16$20,755
MyrbetriqMirabegron41$20,433
LinzessLinaclotide12$18,127
Emgality PenGalcanezumab-Gnlm12$16,677
Tresiba Flextouch U-100Insulin Degludec23$12,219
Breo ElliptaFluticasone/Vilanterol14$11,730
Lantus SolostarInsulin Glargine,hum.Rec.Anlog83$9,826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$183,336175 claims
Novo NordiskOzempic$69$66,31363 claims
GSKTrelegy Ellipta, Breo Ellipta$33$45,62755 claims
AbbVieLinzess, Synthroid$167$20,53165 claims
AstraZenecaSymbicort$12$5,97111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 570 internal medicine providers in Nebraska.

Other internal medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →